tiprankstipranks
Advertisement
Advertisement
Q32 Bio announces $10.5M registered direct offering
PremiumThe FlyQ32 Bio announces $10.5M registered direct offering
2M ago
Q32 Bio Retains Mark Iwicki as Board Chair
Premium
Company Announcements
Q32 Bio Retains Mark Iwicki as Board Chair
4M ago
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
4M ago
Q32 Bio sells complement inhibitor ADX-097 to Akebia
PremiumThe FlyQ32 Bio sells complement inhibitor ADX-097 to Akebia
4M ago
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
5M ago
Q32 Bio reports Q3 EPS (60c), consensus ($1.19)
Premium
The Fly
Q32 Bio reports Q3 EPS (60c), consensus ($1.19)
5M ago
Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
PremiumCompany AnnouncementsQ32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
8M ago
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
8M ago
Q32 Bio Appoints New Interim Chief Medical Officer
Premium
Company Announcements
Q32 Bio Appoints New Interim Chief Medical Officer
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100